Simona Dinicola
Overview
Explore the profile of Simona Dinicola including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
870
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fedeli V, Unfer V, Dinicola S, Lagana A, Canipari R, Monti N, et al.
Cells
. 2024 Jul;
13(14.
PMID: 39056753
Androgen excess is a key feature of several clinical phenotypes of polycystic ovary syndrome (PCOS). However, the presence of FSH receptor (FSHR) and aromatase (CYP19A1) activity responses to physiological endocrine...
2.
Dinicola S, Unfer V, Soulage C, Yap-Garcia M, Bevilacqua A, Benvenga S, et al.
Gynecol Obstet Invest
. 2024 Feb;
89(4):284-294.
PMID: 38373412
Background: <sc>d</sc>-Chiro-inositol is a natural molecule that, in association with its well-studied isomer myo-inositol, may play a role in treating various metabolic and gynecological disorders. Objectives: This perspective seeks to...
3.
Myers S, Russo M, Dinicola S, Forte G, Unfer V
Trends Endocrinol Metab
. 2023 Sep;
34(11):694-703.
PMID: 37661546
Precise diagnoses are essential for defining appropriate treatments. This is particularly true for polycystic ovary syndrome (PCOS), whose phenotypical manifestations have recently suggested a possible diversity of etiological factors. PCOS...
4.
Basciani S, Nordio M, Dinicola S, Unfer V, Gnessi L
Nutrients
. 2023 Jul;
15(14).
PMID: 37513560
The primary control of dysmetabolic patients is extremely challenging worldwide, with inadequate dietary habits and sporadic physical activity among the key risk factors for metabolic syndrome onset. Nowadays, there is...
5.
Kamenov Z, Gateva A, Dinicola S, Unfer V
Metabolites
. 2023 Jun;
13(6).
PMID: 37367875
Despite the beneficial effect of myo-inositol on metabolic, hormonal, and reproductive parameters of polycystic ovary syndrome (PCOS) patients, 28% to 38% could be resistant to this treatment. The combination with...
6.
Monti N, Dinicola S, Querqui A, Fabrizi G, Fedeli V, Gesualdi L, et al.
Cancers (Basel)
. 2023 May;
15(8).
PMID: 37190245
Epithelial-Mesenchymal Transition (EMT), triggered by external and internal cues in several physiological and pathological conditions, elicits the transformation of epithelial cells into a mesenchymal-like phenotype. During EMT, epithelial cells lose...
7.
Unfer V, Dinicola S, Russo M
Int J Mol Sci
. 2023 Apr;
24(7).
PMID: 37047186
A recent evaluation of the published data regarding the PCOS topic has highlighted a paradox in the definition of this condition. Even though the name of the syndrome refers to...
8.
Fedeli V, Cucina A, Dinicola S, Fabrizi G, Catizone A, Gesualdi L, et al.
Int J Mol Sci
. 2022 Feb;
23(4).
PMID: 35216279
Microgravity impairs tissue organization and critical pathways involved in the cell-microenvironment interplay, where fibroblasts have a critical role. We exposed dermal fibroblasts to simulated microgravity by means of a Random...
9.
Dinicola S, Unfer V, Facchinetti F, Soulage C, Greene N, Bizzarri M, et al.
Int J Mol Sci
. 2021 Oct;
22(19).
PMID: 34638926
Myo-inositol (myo-Ins) and D-chiro-inositol (D-chiro-Ins) are natural compounds involved in many biological pathways. Since the discovery of their involvement in endocrine signal transduction, myo-Ins and D-chiro-Ins supplementation has contributed to...
10.
Unfer V, Dinicola S, Lagana A, Bizzarri M
Int J Mol Sci
. 2020 Oct;
21(19).
PMID: 32998310
The presence of abnormal ovarian ratios of myo-inositol (MI) to D-chiro-inositol (DCI) is a recurrent feature in PCOS. Available evidence suggests that MI and DCI may modulate steroid biosynthesis, likely...